Nucleocapsid Antibodies as an Optimal Serological Marker of SARS-CoV-2 Infection: A Longitudinal Study at the Thomayer University Hospital
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001369" target="_blank" >RIV/00064190:_____/25:10001369 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1002/jcla.25149" target="_blank" >https://doi.org/10.1002/jcla.25149</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/jcla.25149" target="_blank" >10.1002/jcla.25149</a>
Alternative languages
Result language
angličtina
Original language name
Nucleocapsid Antibodies as an Optimal Serological Marker of SARS-CoV-2 Infection: A Longitudinal Study at the Thomayer University Hospital
Original language description
BackgroundThe longitudinal study was conducted over the initial 2 years of the COVID-19 pandemic, spanning from June 2020 to December 2022, in healthcare workers (HCWs) of the Thomayer University Hospital. A total of 3892 blood samples were collected and analyzed for total nucleocapsid (N) antibodies. The aim of the study was to evaluate the dynamics of N antibodies, their relationship to the PCR test, spike (S) antibodies, interferon-gamma, and prediction of reinfection with SARS-CoV-2.MethodsBlood collections were performed in three rounds, along with questionnaires addressing clinical symptoms of past infection, PCR testing, and vaccination. Antibody measurements included total N antibodies (Roche Diagnostics) and postvaccination S antibodies (Euroimmun). Cellular immunity was tested by interferon-gamma release assay (Euroimmun).ResultsAt the end of the study, 35.9% of HCWs were positive for N antibodies, and 39.5% of HCWs had either known PCR positivity or N antibodies or both. Ten percent of participants had no knowledge of a COVID-19 infection and 35% of positive individuals exhibited no symptoms. The values of positive antibodies decrease over a period of 6 months to 1 year, depending on the initial value, and their dynamics are highly variable. The study also demonstrated that the highest levels of spike antibodies and interferon-gamma occur during so-called hybrid immunity.ConclusionNucleocapsid antibodies proved valuable in monitoring SARS-CoV-2 infection dynamics, and they may detect cases of SARS-CoV-2 infection missed by PCR tests. The study identified distinct patterns in antibody dynamics and protection of hybrid immunity during reinfection.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30502 - Other medical science
Result continuities
Project
<a href="/en/project/NU22-A-123" target="_blank" >NU22-A-123: Prognostic factors affecting treatment outcomes and mortality in COVID-19 patients, new diagnostic methods, current and new terapeutic opportunities for COVID-19</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
JOURNAL OF CLINICAL LABORATORY ANALYSIS
ISSN
0887-8013
e-ISSN
1098-2825
Volume of the periodical
39
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
nestránkováno
UT code for WoS article
001389906500001
EID of the result in the Scopus database
2-s2.0-85214382773